Liver in F1-TKm30 mice: Control vs 4,4'-Methylenebis(2-chlorobenzenamine) treatment
The gene expression profling between Control and 4,4'-Methylenebis(2-chlorobenzenamine) exposure for 4 weeks in liver of F1-TKm30 female mice. Overall design: Female 17- or 21-week-old NOG mice expressing HSVtk mutant clone 30 cDNA under the control of mouse transthyretin gene enhancer/promoter (F1-TKm30 mice) were treated with 0 or 0.05% 4,4'-Methylenebis(2-chlorobenzenamine) (MOCA) for 4 weeks. After treatment, mice were sacrificed, and removed livers. Control and MOCA treatment: 4 control female mice, 4 MOCA-treated female mice, respectively.